| |
FN Patients (n = 295)
|
Comparison Patients (n = 295)
|
P-value*
|
|---|
|
Demographics
|
| |
Age, mean±SD, y
| | | |
63.3 ± 12.4
|
63.0 ±12.1
|
0.108
|
| |
Male, %
| | | |
49.0
|
50.7
|
0.674
|
| |
Country of Residence
|
| | |
Australia
| | |
2.7
|
2.7
|
0.817
|
| | |
Austria
| | |
5.8
|
9.2
| |
| | |
Belgium
| | |
11.6
|
11.9
| |
| | |
France
| | |
24.5
|
18.4
| |
| | |
Germany
| | |
10.2
|
12.2
| |
| | |
Greece
| | |
2.7
|
1.7
| |
| | |
Italy
|
5.1
|
7.8
| | | |
| | |
Netherlands
| | |
8.8
|
8.5
| |
| | |
Nordics
| | |
7.1
|
6.5
| |
| | |
Portugal
| | |
1.4
|
1.7
| |
| | |
Spain
| | |
12.6
|
12.6
| |
| | |
Switzerland
| | |
2.7
|
2.4
| |
| | |
UK and Ireland
| | |
4.8
|
4.4
| |
|
NHL
|
| |
Tumor Stage
|
| |
I
| | | |
14.6
|
14.6
|
---
|
| |
II
| | | |
16.7
|
16.7
| |
| |
III
| | | |
19.4
|
19.4
| |
| |
IV
| | | |
49.3
|
49.3
| |
| |
IPI/FLIPI Score
|
| | |
IPI Score
|
| | | |
Low
| |
16.4
|
20.8
|
0.368
|
| | | |
Intermediate
| |
50.4
|
50.6
| |
| | | |
High
| |
19.6
|
17.3
| |
| | | |
Missing
| |
13.6
|
11.4
| |
| | |
FLIPI score
|
| | | |
Low Risk
| |
11.4
|
15.4
|
0.920
|
| | | |
Intermediate Risk
| |
36.4
|
23.1
| |
| | | |
Poor Risk
| |
43.2
|
51.3
| |
| | | |
Missing
| |
9.1
|
10.3
| |
| | |
Bone Marrow Involvement
| | |
29.6
|
24.8
|
0.252
|
|
Clinical
|
| |
Risk of FN, %
|
| | |
<20%
| | |
27.0
|
27.0
|
0.564
|
| | |
≥ 20%
| | |
73.0
|
73.0
| |
| |
Medical Conditions, %
|
| | |
Cardiovascular Disease
| | |
23.5
|
25.2
|
0.615
|
| | |
Respiratory Disease
| | |
7.8
|
4.8
|
0.128
|
| | |
Gastrointestinal Disease
| | |
6.1
|
5.1
|
0.564
|
| | |
Renal Disease
| | |
3.1
|
3.4
|
0.796
|
| | |
Hepatic/Biliary Disease
| | |
2.7
|
5.8
|
0.061
|
| | |
Haematologic/Lymphatic
| | |
5.1
|
3.1
|
0.221
|
| | |
Immunologic
| | |
5.4
|
3.7
|
0.317
|
| | |
Other
| | |
49.0
|
46.3
|
0.505
|
| |
ECOG PS, %
|
| | |
0
| | |
47.6
|
52.4
|
0.182
|
| | |
1
| | |
31.0
|
31.6
| |
| | |
2
| | |
10.2
|
7.5
| |
| | |
3
| | |
5.1
|
3.7
| |
| | |
4
| | |
1.0
|
0.7
| |
| | |
Missing
| | |
5.1
|
4.1
| |
| |
Hematology
|
| | |
ANC (X10^9L), mean±SD
| | |
5.4 ± 4.5
|
5.7 ± 3.4
|
0.794
|
| | |
Presence of Anemia Symptoms, %
| | |
56.8
|
56.1
|
0.856
|
|
Treatment
|
| |
Chemotherapy Regimen, %
|
| | |
CHOP-14
| | |
3.40
|
3.40
|
---
|
| | |
CHOP-14-R
| | |
27.89
|
27.89
| |
| | |
CHOP-21
| | |
5.44
|
5.44
| |
| | |
CHOP-21-R
| | |
63.27
|
63.27
| |
| |
Supportive Care, %
|
| | |
Index Cycle
|
| | | |
G-CSF Prophylaxis
| |
51.7
|
56.5
|
0.162
|
| | | |
Anti-Infective FN Prophylaxis
| |
13.3
|
11.6
|
0.529
|
| | |
Pre-Index Cycle
|
| | | |
G-CSF
|
| | | | |
Prophylaxis
|
37.4
|
41.8
|
0.074
|
| | | | |
Treatment
|
9.5
|
6.5
|
0.128
|
| | | |
Anti-Infective
|
| | | | |
FN Prophylaxis
|
7.8
|
5.8
|
0.303
|
| | | | |
FN Treatment
|
1.7
|
0.3
|
0.102
|
| | | |
Transfusion
| |
9.5
|
6.8
|
0.144
|
| |
Index Cycle Number*
|
| |
1
| | | |
42.9
|
42.9
|
---
|
| |
2
| | | |
13.6
|
13.6
| |
| |
3
| | | |
11.2
|
11.2
| |
| |
4
| | | |
12.2
|
12.2
| |
| |
5
| | | |
9.9
|
9.9
| |
| |
6
| | | |
8.2
|
8.2
| |
| |
7
| | | |
1.7
|
1.7
| |
| |
8
| | | |
0.3
|
0.3
| |
| |
Total Number of Cycles (incl. index cycle thru end of course)
|
| |
1
| | | |
10.6
|
11.2
|
0.812
|
| |
2
| | | |
11.9
|
9.5
| |
| |
3
| | | |
13.3
|
11.6
| |
| |
4
| | | |
12.3
|
15.3
| |
| |
5
| | | |
12.6
|
11.6
| |
| |
6
| | | |
24.2
|
24.8
| |
| |
7
| | | |
4.1
|
4.1
| |
| |
8
| | | |
10.9
|
11.9
| |
- *P-values were not calculated for variables used in the matching process and for which there are no differences between groups (i.e., there was an exact match).
